Merck & Co., Inc. MRK

NYSE · Healthcare · Drug Manufacturers - General

$133.72

Close on Fri, 20 Nov 2026 · market value $330B

What the price is betting on

Below its record

At $134, the price assumes revenue shrinks about 0.7% a year for five years, from $67.3B to about $65.2B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.

The price assumes−0.7%
Analysts, next two years3.8%
Last 3 years4.2%

Revenue growth a year. The price figure comes from a reverse DCF at a 6.4% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than MRK? Check up to 5 of your stocks at once, free, no account.

0$20B$40B$60B$80B$67.3B'22'23'24'25Sep '26'26'27'28'29'30What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$151

Base

$170

Bull

$191

Today $134

  • Bear $151. Cash flow grows 1% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $170. Cash flow grows 3% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $191. Cash flow grows 5% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2026$67.2B$67.2B, on the path
  3. FY2027$66.7B$69.4B, on the path
  4. FY2028$66.2B$73.6B, on the path
  5. FY2029$65.7B$74.2B, on the path
  6. FY2030$65.2B$74.9B, on the path

Each year's revenue at −0.7% growth from $67.3B in the 12 months to September 2026.

At a glance

Healthcare · Drug Manufacturers - General · listed on NYSE

Revenue, FY2025
$64.9B
Growth, 3 years a year
4.2%
Cash margin
19%
Net debt
$36B
Shares, 3-year change
−1.4%
Dividend yield
2.5%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.